Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19246586 | FUSION ANTIGEN OF PORCINE GETAH VIRUS, KIT, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | June 2025 | December 2025 | Allow | 6 | 1 | 0 | No | No |
| 19091651 | Methods of Detecting, Identifying and Quantifying Wild Spike Protein and Covid Vaccine Spike Proteins | March 2025 | November 2025 | Allow | 8 | 2 | 0 | No | No |
| 18777836 | C-BASED SINGLE DOMAIN ANTIBODY FOR NEUTRALIZING RESPIRATORY SYNCYTIAL VIRUS AND APPLICATION THEREOF | July 2024 | April 2025 | Allow | 9 | 1 | 0 | No | No |
| 18601925 | BROAD-SPECTRUM MULTI-ANTIGEN PAN-CORONAVIRUS VACCINE | March 2024 | October 2025 | Allow | 19 | 3 | 0 | Yes | No |
| 18512036 | MULTIPLEXED NUCLEIC ACID DETECTION KIT FOR HUMAN PAPILLOMAVIRUS (HPV) TYPING, AND DETECTION METHOD | November 2023 | August 2024 | Allow | 9 | 1 | 0 | No | No |
| 18277087 | Recombinant Severe Acute Respiratory Syndrome Coronavirus 2 Rbd Trimer Protein Vaccine Capable Of Generating Broad-Spectrum Cross Neutralization Activity, and Preparation Method and Use Thereof | August 2023 | April 2025 | Allow | 20 | 2 | 0 | No | No |
| 18227747 | METHODS OF MANUFACTURING GENETICALLY-MODIFIED LYMPHOCYTES | July 2023 | November 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18158273 | PHARMACEUTICAL FORMULATIONS OF FCRN INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION | January 2023 | November 2025 | Abandon | 34 | 2 | 0 | No | No |
| 17913986 | RECOMBINANT VIRUSES, INSECT CELLS AND THEIR USES IN VIRAL DETECTION AND VACCINATION | September 2022 | November 2025 | Allow | 38 | 1 | 0 | No | No |
| 17800700 | PURIFICATION MATRICES COMPRISING AAV-BINDING POLYPEPTIDES AND METHODS OF USING THE SAME | August 2022 | November 2025 | Allow | 39 | 1 | 0 | No | No |
| 17904535 | PROTEIN-BASED PURIFICATION MATRICES AND METHODS OF USING THE SAME | August 2022 | January 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17797438 | TREATMENT OF HPV-RELATED DISEASES | August 2022 | January 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17827320 | SYNTHETIC CHIMERIC POXVIRUSES | May 2022 | November 2024 | Allow | 29 | 1 | 0 | No | No |
| 17780093 | NOVEL VERO CELL LINE THAT CAN BE SUSPENSION-CULTURED IN SERUM-FREE MEDIUM, PREPARATION METHOD THEREFOR, AND METHOD FOR PREPARING VIRUSES FOR VACCINES BY USING NOVEL CELL LINE | May 2022 | September 2025 | Allow | 40 | 1 | 0 | No | No |
| 17746859 | SARS-COV-2 SPIKE PROTEIN ANTIBODIES | May 2022 | November 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17737991 | ATTENUATING VIRAL MUTATIONS IN PROTEIN GENES | May 2022 | March 2025 | Allow | 34 | 3 | 0 | No | No |
| 17662141 | Vaccines Against Coronavirus and Methods of Use | May 2022 | October 2025 | Allow | 42 | 3 | 0 | No | No |
| 17717504 | RECOMBINANT RSV LIVE VACCINE STRAIN AND THE PREPARING METHOD THEREOF | April 2022 | February 2025 | Allow | 34 | 2 | 0 | No | No |
| 17633876 | Machine Methods To Determine Neoepitope Payload Toxicity | February 2022 | October 2025 | Allow | 44 | 1 | 0 | No | No |
| 17578049 | AMINO ACID SEQUENCE DERIVED FROM S PROTEIN OF SARS-COV2 FOR GENERATING AN ANTI-SARS -COV-2 ANTIBODY | January 2022 | March 2025 | Allow | 37 | 3 | 0 | No | No |
| 17626206 | ANTIGENIC GLYCOPROTEIN E POLYPEPTIDES, COMPOSITIONS, AND METHODS OF USE THEREOF | January 2022 | October 2025 | Allow | 45 | 1 | 0 | No | No |
| 17596732 | METHOD FOR PRODUCING A VIRUS AND A HARVESTING SOLUTION COMPOSITION | December 2021 | October 2025 | Allow | 46 | 1 | 0 | No | No |
| 17609496 | Zika Virus Constructs and Therapeutic Compositions Thereof | November 2021 | July 2025 | Allow | 45 | 1 | 0 | No | No |
| 17513538 | HIGH THROUGHPUT IMMUNOASSAYS AND METHODS FOR THE DETECTION OF SARS-COV-2 ANTIGENS | October 2021 | November 2024 | Abandon | 36 | 2 | 0 | No | No |
| 17603221 | METHODS AND COMPOSITIONS FOR IMPROVING THE ASSEMBLY OF ADENO-ASSOCIATED VIRUSES (AAVs) | October 2021 | December 2025 | Allow | 50 | 1 | 0 | No | No |
| 17602199 | METHODS OF SIZE EXCLUSION CHROMATOGRAPHY FOR THE CHARACTERIZATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS COMPOSITIONS | October 2021 | October 2025 | Allow | 49 | 1 | 0 | No | No |
| 17599578 | USE OF PRIMER PROBE COMBINATION AND KIT THEREOF IN HBV DETECTION | September 2021 | November 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17598582 | RECOMBINANT PROTEINS WITH CD40 ACTIVATING PROPERTIES | September 2021 | November 2025 | Allow | 50 | 1 | 0 | No | No |
| 17593446 | A LIVE AND ATTENUATED FLAVIVIRUS COMPRISING A MUTATED M PROTEIN | September 2021 | June 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17438047 | NOROVIRUS-LIKE PARTICLES WITH IMPROVED STABILITY | September 2021 | October 2025 | Allow | 50 | 2 | 0 | No | No |
| 17437470 | HIGHLY NETWORKED IMMUNOGEN COMPOSITION | September 2021 | December 2025 | Allow | 51 | 2 | 0 | No | No |
| 17436782 | FILOVIRUS ANTIBODIES AND METHODS | September 2021 | December 2024 | Allow | 39 | 1 | 0 | No | No |
| 17435590 | METHOD FOR PRODUCING INFLUENZA HA SPLIT VACCINE | September 2021 | August 2025 | Allow | 47 | 2 | 0 | No | No |
| 17434489 | Multivalent Live-attenuated Influenza Vaccine for Prevention and Control of Equine Influenza Virus (EIV) in Horses | August 2021 | March 2025 | Allow | 42 | 1 | 0 | No | No |
| 17400041 | ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOF | August 2021 | December 2024 | Allow | 40 | 2 | 0 | No | No |
| 17430018 | RECOMBINANT HERPES SIMPLEX VIRUS HAVING MODIFIED GLYCOPROTEIN GH FOR RETARGETING AND USE THEREOF | August 2021 | December 2024 | Allow | 40 | 2 | 0 | No | No |
| 17429792 | CHIMERIC RSV AND HMPV F PROTEINS, IMMUNOGENIC COMPOSITIONS, AND METHODS OF USE | August 2021 | October 2025 | Allow | 50 | 3 | 0 | No | No |
| 17427844 | IN VITRO METHOD FOR THE DIAGNOSIS OF VIRAL INFECTIONS | August 2021 | December 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17427569 | IMMUNOCHROMATOGRAPHY ANALYSIS DEVICE FOR DETECTING DENGUE VIRUS | July 2021 | January 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17389724 | ANTI-CORONAVIRUS VACCINES | July 2021 | January 2025 | Allow | 41 | 2 | 1 | No | No |
| 17387409 | METHOD FOR MEASURING VIRAL ANTIGEN IN SAMPLE, ANTIBODY SET, AND REAGENT KIT | July 2021 | March 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17426043 | PRODUCTION OF VIRUSES IN CONTINUOUSLY GROWING EPITHELIAL CELL LINES DERIVED FROM CHICKEN GUT | July 2021 | February 2025 | Allow | 43 | 1 | 0 | No | No |
| 17310239 | NUCLEIC ACID DELIVERY COMPLEX | July 2021 | July 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17425791 | POLYPEPTIDES DIRECTED AGAINST VIRAL INFECTION AND USES THEREOF | July 2021 | March 2025 | Allow | 43 | 1 | 0 | No | No |
| 17425534 | METHODS FOR SCREENING POLYPEPTIDES CAPABLE OF BINDING SPECIFIC TARGET MOLECULES AND TOOLS RELATED THERETO | July 2021 | July 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17425618 | SEED CULTURE PROCESS FOR AAV PRODUCTION | July 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17305796 | VIROFIND: A NOVEL PLATFORM FOR DETECTION AND DISCOVERY OF THE ENTIRE VIROGENOME IN CLINICAL SAMPLES | July 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17421816 | USE OF HLA-A*11:01-RESTRICTED HEPATITIS B VIRUS (HBV) PEPTIDES FOR IDENTIFYING HBV-SPECIFIC CD8+ T CELLS | July 2021 | April 2025 | Allow | 46 | 2 | 0 | No | No |
| 17421541 | FOOT-AND-MOUTH DISEASE VIRUS-LIKE PARTICLE ANTIGEN, AND VACCINE COMPOSITION, PREPARATION METHOD, AND APPLICATION THEREOF | July 2021 | December 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17369691 | Method for the Detection of Surface-Mounted Biological Materials and Pathogens | July 2021 | October 2025 | Abandon | 51 | 2 | 0 | No | No |
| 17368711 | METHODS FOR QUANTITATIVE ANALYSIS OF ONE OR MORE BIOMARKERS | July 2021 | October 2025 | Allow | 51 | 1 | 1 | No | No |
| 17419792 | RECOMBINANT ONCOLYTIC NEWCASTLE DISEASE VIRUSES WITH INCREASED ACTIVITY | June 2021 | August 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17419171 | DUX4 RNA Silencing Using RNA Targeting CRISPR-CAS13b | June 2021 | November 2025 | Allow | 52 | 3 | 0 | No | No |
| 17414759 | SERUM-FREE MEDIUM FOR AVIAN VACCINE PRODUCTION AND USES THEREOF | June 2021 | June 2025 | Allow | 48 | 3 | 0 | No | No |
| 17413853 | PATHOGEN-ASSOCIATED MOLECULAR PATTERN MOLECULES AND RNA IMMUNOGENIC COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR TREATING CANCER | June 2021 | January 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17413203 | HETEROLOGOUS PRIME BOOST VACCINE COMPOSITIONS AND METHODS | June 2021 | March 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17413228 | PRODUCTION OF VIRAL VACCINES ON AN AVIAN CELL LINE | June 2021 | November 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17299520 | ENGINEERED HANSENULA FUNGI EFFICIENTLY EXPRESSING CA10 VIRUS-LIKE PARTICLES AND USES THEREOF | June 2021 | November 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17294414 | HYBRIDOMA CELL LINE FOR SECRETING ANTI-RABIES VIRUS M PROTEIN MONOCLONAL ANTIBODY AND APPLICATION THEREOF | May 2021 | January 2026 | Allow | 57 | 1 | 0 | No | No |
| 17293364 | STABILIZED PRE-FUSION RSV F PROTEINS | May 2021 | February 2025 | Allow | 45 | 2 | 0 | No | No |
| 17290054 | ANTI-HIV ANTIBODY AND METHOD FOR PRODUCING SAME | April 2021 | November 2025 | Allow | 54 | 3 | 0 | No | No |
| 17242979 | COMPOSITIONS AND METHODS COMPRISING MEASLES VIRUS DEFECTIVE INTERFERING PARTICLES FOR THE PREVENTION OF INFECTIOUS DISEASES | April 2021 | October 2025 | Allow | 54 | 3 | 0 | No | No |
| 17289336 | SYSTEM FOR PROTEIN INACTIVATION AND RECOMBINANT PHAGES FOR TARGETED BACTERIAL KILLING, INFECTION, BIODETECTION, AND AS A MEANS OF PROTEIN EXTRACTION | April 2021 | October 2024 | Allow | 41 | 1 | 0 | No | No |
| 17287188 | ANTI-HIV ANTIBODIES | April 2021 | September 2025 | Allow | 53 | 2 | 1 | No | No |
| 17231415 | SIV ENVELOPE TRIMER | April 2021 | December 2024 | Allow | 44 | 2 | 0 | Yes | No |
| 17279330 | NOVEL VIRUS VECTOR AND METHODS FOR PRODUCING AND USING SAME | March 2021 | November 2025 | Abandon | 56 | 4 | 0 | No | No |
| 17269955 | COMPOSITIONS AND METHODS FOR MODULATING TRANSDUCTION EFFICIENCY OF ADENO-ASSOCIATED VIRUSES | February 2021 | August 2024 | Allow | 42 | 1 | 1 | No | No |
| 17261501 | METHODS FOR SCREENING AND IDENTIFYING AGENTS THAT INHIBIT OR MODULATE THE NUCLEAR EGRESS COMPLEX OF HERPESVIRUSES | January 2021 | October 2024 | Allow | 45 | 1 | 0 | No | No |
| 17132607 | CAPSID-MODIFIED, RAAV3 VECTOR COMPOSITIONS AND METHODS OF USE IN GENE THERAPY OF HUMAN LIVER CANCER | December 2020 | October 2025 | Allow | 58 | 3 | 1 | No | No |
| 17055151 | VIRUS VECTOR PRODUCTION | November 2020 | March 2025 | Allow | 52 | 2 | 0 | Yes | No |
| 17050608 | SCALABLE CLARIFICATION PROCESS FOR RECOMBINANT AAV PRODUCTION | October 2020 | March 2025 | Allow | 52 | 1 | 0 | No | No |
| 17042043 | METHODS OF MANUFACTURING GENETICALLY-MODIFIED LYMPHOCYTES | September 2020 | April 2025 | Abandon | 55 | 2 | 0 | No | Yes |
| 16962748 | MODIFIED RAAV CAPSID PROTEIN FOR GENE THERAPY | July 2020 | July 2025 | Allow | 60 | 3 | 0 | No | No |
| 16954988 | ANTIGEN BINDING POLYPEPTIDES | June 2020 | July 2025 | Abandon | 60 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STUART, CAREY ALEXANDER MC.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner STUART, CAREY ALEXANDER MC works in Art Unit 1671 and has examined 53 patent applications in our dataset. With an allowance rate of 69.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 46 months.
Examiner STUART, CAREY ALEXANDER MC's allowance rate of 69.8% places them in the 32% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by STUART, CAREY ALEXANDER MC receive 1.74 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by STUART, CAREY ALEXANDER MC is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +34.0% benefit to allowance rate for applications examined by STUART, CAREY ALEXANDER MC. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 46.2% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 42.9% of cases where such amendments are filed. This entry rate is in the 65% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 62.5% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 27.0% of allowed cases (in the 95% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.